4//SEC Filing
Boudes Pol F 4
Accession 0001133416-24-000008
CIK 0001133416other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:43 PM ET
Size
7.8 KB
Accession
0001133416-24-000008
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-24+65,000→ 65,000 totalExercise: $1.11Exp: 2034-01-24→ Common Stock (65,000 underlying) - Award
Restricted Stock Unit
2024-01-24+40,000→ 40,000 total→ Common Stock (40,000 underlying)
Footnotes (4)
- [F1]The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024.
- [F3]The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
- [F4]Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0001454771
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 4:43 PM ET
- Size
- 7.8 KB